To Be “Fit For 2018,” Merck Serono Hints At Earlier Stage Deals, But India May Have To Wait
This article was originally published in PharmAsia News
Executive Summary
The world’s oldest drug maker is gearing up to be a leaner machine by 2018, relying on studying data closely before signing deals.
You may also be interested in...
Merck KGaA's Softly-Softly Approach To German Cutbacks Shows Learning From Swiss Experience
Merck KGaA is in learning mode as it calls for early retirements and voluntary redundancies in Germany, instead of more abrupt action. Around 10% of jobs at Merck KGaA in Germany are at risk, but the company will refrain from forced job losses until the end of 2017.
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.